


PHARMACEUTICAL 2022



Amneal Pharmaceuticals Inc. Rank 133 of 475





PHARMACEUTICAL 2022



Amneal Pharmaceuticals Inc. Rank 133 of 475

The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 259% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 290% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	1,520,108
Cost of Goods Sold	1,302,004
Intangible Assets	1,759,939
Liabilities, Current	677,243
Liabilities, Non-Current	2,878,541
Other Assets	145,459
Other Compr. Net Income	7,171
Other Expenses	57,794
Other Liabilities	0
Other Net Income	-146,350
Property and Equipment	514,158
Research and Development	201,847
Revenues	2,093,669
Selling, General and Administrative Expense	365,504

Output Variable	Value in 1000 USD
Assets	3,939,664
Liabilities	3,555,784
Expenses	1,927,149
Stockholders Equity	383,880
Net Income	20,170
Comprehensive Net Income	23,756
Economic Capital Ratio	14%